Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Study of a New Technique for Imaging Pancreatic Cancer
      Description

      The purpose of this study is to see how well the experimental imaging agent 89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done with this imaging agent produce better images of cancer.

      Conditions
      Pancreatic CancerTumors That Express CA19-9
      Talk to us
      TERMINATED
      Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
      Description

      Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing PET scans. The study is designed to determine the best time and dose of these agents that result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for imaging and a clinical assessment. The last study visit is on day 28.

      Conditions
      Pancreatic CarcinomaTumors That Express CA19-9
      Talk to us
      TERMINATED
      Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
      Description

      Open label, nonrandomized, dose-escalation with cohort expansion study of MVT-5873/MVT-1075 in subjects with previously treated, Carbohydrate Antigen 19-9 (CA19-9) positive malignancies (e.g., pancreatic adenocarcinoma).

      Conditions
      Pancreatic CarcinomaTumors That Express CA 19-9
      Talk to us